Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 4:6:138.
doi: 10.3389/fpubh.2018.00138. eCollection 2018.

Is the Rise in the Prevalence of Renal Replacement Therapy at Older Ages the Price for Living Longer?

Frederik Peters  1   2 , Christina Westphal  3 , Anneke Kramer  4 , Ronny Westerman  5
Affiliations

Is the Rise in the Prevalence of Renal Replacement Therapy at Older Ages the Price for Living Longer?

Frederik Peters et al. Front Public Health. .

Abstract

Background: Renal replacement therapy (RRT) is one of the most expensive in renal medicine. Cross-sectional studies suggest that life expectancy increases in the general population are associated with a higher burden of RRT. This study tests this hypothesis in a prospective setting among people aged 75+ living in Western Europe.

Methods: We gathered sex-specific data for 11 Western European countries in 2005-2014. RRT prevalence on country level was extracted from the ERA-EDTA registry, while data on population size and life expectancy for the 75+ age group came from the Eurostat database. GDP per capita was extracted from the OECD database. To measure the association between RRT prevalence and life expectancy, we performed Poisson regression models separately for each country and for all countries combined. To adjust for confounding, GDP per capita as well as time and country-fixed effects were included.

Results: Our analysis revealed that living longer coincides with rising RRT prevalence at ages 75+ in Western Europe between 2005 and 2014. On average, a 1-year increase in life expectancy was associated with a roughly 20% increase in RRT prevalence [(95% CI) 21-23% in men and 19-22% in women]. However, after adjustments for confounding were made, the association became insignificant among women and became weaker among men, falling to a level of 11% [(95% CI) 6-17%].

Conclusion: Living longer was not necessarily associated with a higher burden of RRT in Western European countries.

Keywords: Europe; elderly population; end-stage renal disease; life expectancy; renal replacement therapy.

PubMed Disclaimer

References

    1. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (2016) 388:1459–544.10.1016/S0140-6736(16)31575-6 - DOI - PMC - PubMed
    1. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet (2009) 374:1196–208.10.1016/S0140-6736(09)61460-4 - DOI - PMC - PubMed
    1. Kontodimopoulos N, Niakas D. An estimate of lifelong costs and QALYs in renal replacement therapy based on patients’ life expectancy. Health Policy (2008) 86:85–96.10.1016/j.healthpol.2007.10.002 - DOI - PubMed
    1. Rodina-Theocharaki A, Bliznakova K, Pallikarakis N. Markov Chain Monte Carlo simulation for projection of end stage renal disease patients in Greece. Comput Methods Programs Biomed (2012) 107:90–6.10.1016/j.cmpb.2011.09.012 - DOI - PubMed
    1. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet (2015) 385:1975–82.10.1016/S0140-6736(14)61601-9 - DOI - PubMed

LinkOut - more resources